Lupus Nephritis - Epidemiology Forecast - 2032

Key Highlights

• Lupus nephritis is a severe, organ-threatening manifestation of systemic lupus erythematosus (SLE), developed in 40-60% of patients with SLE. Signs of lupus nephritis include hematuria (blood in the urine) and proteinuria (protein in the urine). Lupus nephritis is more common in women and occurs in patients aged 20-40.
• In 2022, the total prevalent cases of lupus nephritis were highest in the US among the 7MM, accounting for approximately 144,000 cases, expected to increase by 2032.
• The prevalence of focal proliferative lupus nephritis (Class III) accounts for ~30%, diffuse proliferative lupus nephritis (Class IV) for ~40%, and membranous lupus nephritis (Class V) for ~20%.
• Juvenile-onset SLE patients exhibit a higher prevalence of lupus nephritis (50-82%) than adult SLE patients (34-53%).

This “Lupus Nephritis - Epidemiology Forecast - 2032” report delivers an in-depth understanding of Lupus Nephritis, historical and forecasted epidemiology trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Geography Covered

• The United States
• EU4 (Germany, France, Italy, and Spain) and the United Kingdom
• Japan

Study Period: 2019-2032

Lupus Nephritis Disease Understanding and Treatment Algorithm

Lupus Nephritis Overview

There are two types of lupus. Systemic lupus erythematosus (SLE) is a form of lupus that can harm the skin, joints, kidneys, and brain and may be fatal. The other form of lupus is called “discoid” lupus erythematosus, which only affects the skin. When SLE affects the kidneys, it is called lupus nephritis. Lupus is an “autoimmune” disease, meaning the immune system (the body's defense system), which usually protects the body from disease, turns against the body. This causes harm to organs and tissues, like kidneys. It results in inflammation (swelling or scarring) of the small blood vessels that filter wastes in the kidney (glomeruli). Lupus nephritis can be classified as follows: Class I, minimal mesangial lupus nephritis; Class II, mesangial proliferative lupus nephritis; Class III, focal lupus nephritis (active and chronic, proliferative and sclerosing); Class IV, diffuse lupus nephritis (active and chronic, proliferative and sclerosing, segmental and global); Class V, membranous lupus nephritis; Class VI: advanced sclerosis lupus nephritis.

Lupus Nephritis Diagnosis

Lupus nephritis is diagnosed through urine and blood tests and a kidney biopsy. One of the first signs of lupus nephritis is blood in the urine or extremely foamy urine. High blood pressure and swelling in the feet also might indicate lupus nephritis. Tests that will help the doctor make a diagnosis include the following: blood tests, urine tests, including a 24-hour urine collection, kidney ultrasound, kidney biopsy, etc.

Further details related to diagnosis are provided in the report.

Lupus Nephritis Epidemiology

The lupus nephritis epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by total diagnosed prevalent cases of SLE, total prevalent cases of lupus nephritis, and diagnosed and treated cases of lupus nephritis in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan from 2019 to 2032.

• The total diagnosed prevalent cases of SLE in the 7MM comprised approximately 657,000 cases in 2022 and are projected to increase during the forecasted period.
• The United States contributed to the largest prevalent cases of lupus nephritis, accounting for approximately 50% of the 7MM in 2022. Whereas EU4 the UK, and Japan accounted for around 36% and 14% of the total population share, respectively, in 2022.
• The total diagnosed and treated cases of lupus nephritis in the US comprised nearly 130,000 cases in 2022.
• Among EU4 and the UK, the UK accounted for the largest number of lupus nephritis cases, followed by Germany, whereas France accounted for the lowest number of cases in 2022.

KOL Views

To keep up with current epidemiology trends, we take KOLs and SMEs' opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry experts contacted for insights on lupus nephritis evolving treatment landscape, patient reliance on conventional therapies, patient's therapy switching acceptability, and drug uptake, along with challenges related to accessibility, include Medical/scientific writers; National Kidney Foundation; Rheumatologist and Professors; MD, FACS, Chair of the Department of Department of Nephrology and Rheumatology Surgery, and Kidney Disease Center; and others.

This analysts connected with 30+ KOLs to gather insights; however, interviews were conducted with 10+ KOLs in the 7MM. Centers such as the Center for Kidney Diseases, Department of Rheumatology, Department of Nephrology, etc., were contacted. Their opinion helps understand and validate lupus nephritis epidemiology trends.

Scope of the Report

• The report covers a segment of key events, an executive summary, descriptive overview of Lupus Nephritis, explaining its causes, signs and symptoms, pathogenesis, and currently available therapies.
• Comprehensive insight into the epidemiology segments and forecasts of disease progression has been provided.
• The report provides an edge while developing business strategies, understanding trends, expert insights/KOL views, and patient journeys in the 7MM.
• A detailed review of current challenges in establishing the diagnosis.

Lupus Nephritis Report Insights

• Patient Population
• Country-wise Epidemiology Distribution

Lupus Nephritis Report Key Strengths

• Ten Years Forecast
• The 7MM Coverage
• Lupus Nephritis Epidemiology Segmentation

Lupus Nephritis Report Assessment

• Current Diagnostic Practices
• Unmet Needs

FAQs

• What are the disease risks, burdens, and unmet needs of Lupus Nephritis? What will be the growth opportunities across the 7MM concerning the patient population with Lupus Nephritis?
• What is the historical and forecasted Lupus Nephritis patient pool in the United States, EU4 (Germany, France, Italy, and Spain) the United Kingdom, and Japan?
• Which type of Lupus Nephritis is the largest contributor?
• What is the diagnosis rate of Lupus Nephritis?

Reasons to Buy

• Insights on patient burden/disease, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand the diagnosed cases of Lupus Nephritis in varying geographies over the coming years.
• To understand the perspective of key opinion leaders around the current challenges with establishing the diagnosis and insights on the recurrent and treatment-eligible patient pool.
• Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.